Tucatinib Improves Breast Cancer Treatment Outcomes
Here’s a breakdown of the key details from the provided text, focusing on Tucatinib and the HER2Climb-05 study:
Key Findings & Information about Tucatinib & HER2Climb-05:
* HER2Climb-05 Study: This Phase 3 study investigated tucatinib added to standard treatment (trastuzumab and pertuzumab) as maintenance therapy for HER2+ metastatic breast cancer.
* Extended Disease Control: integrating tucatinib into first-line maintenance therapy significantly extends disease control.
* Delay to Chemotherapy: The treatment provides a longer period before patients need to start cytotoxic chemotherapy.
* Efficacy: tucatinib, in combination with trastuzumab and pertuzumab, represents an enhanced first-line maintenance therapy option.
* Diarrhea as a Side effect:
* Diarrhea was the most frequently reported treatment-related adverse event (TEAE).
* Any-grade diarrhea occurred in 72% of patients.
* Grade 3 or higher diarrhea occurred in 6.1% of patients.
* Diarrhea typically resolved within 8 days of onset (median).
* Dose modifications were relatively uncommon: 6% required a dose reduction, and 1.5% discontinued tucatinib due to diarrhea.
* Manageable Safety Profile: The study suggests a manageable safety profile overall.
References:
- Clinical Trial: https://clinicaltrials.gov/study/NCT05132582 (HER2CLIMB-05)
- Presentation: Hamilton E, Curigliano G, Martin M. Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer. Presented at: SABCS 2025. December 9-12, 2025. San Antonio, TX.